tiprankstipranks
Trending News
More News >

Telix Pharmaceuticals Announces Cessation of Share Rights

Story Highlights
Telix Pharmaceuticals Announces Cessation of Share Rights

Confident Investing Starts Here:

An update from Telix Pharmaceuticals ( (AU:TLX) ) is now available.

Telix Pharmaceuticals Limited has announced the cessation of 135,000 share rights under the ASX security code TLXAP, effective May 16, 2025. This announcement may impact the company’s capital structure and could have implications for its stakeholders, as it reflects changes in the company’s issued securities.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$19.30 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of diagnostic and therapeutic products using molecularly targeted radiation (MTR). The company aims to address significant unmet medical needs in oncology and rare diseases, leveraging its expertise in radiopharmaceuticals to enhance patient care.

Average Trading Volume: 1,968,807

Technical Sentiment Signal: Buy

Current Market Cap: A$8.64B

See more data about TLX stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App